Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1977 1
1980 1
1990 1
1991 1
1993 2
1998 1
1999 1
2002 1
2003 1
2004 1
2005 4
2006 4
2007 8
2008 9
2009 6
2010 15
2011 14
2012 6
2013 9
2014 3
2015 4
2016 9
2017 5
2018 7
2019 2
2020 4
2021 3
2022 7
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study.
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A; LCIG Horizon Study Group. Olanow CW, et al. Lancet Neurol. 2014 Feb;13(2):141-9. doi: 10.1016/S1474-4422(13)70293-X. Epub 2013 Dec 20. Lancet Neurol. 2014. PMID: 24361112 Free PMC article. Clinical Trial.
[Relevance of COMT inhibitors in the treatment of motor fluctuations].
Jost WH, Buhmann C, Classen J, Eggert K, Kohl Z, Outeiro T, Tönges L, Woitalla D, Reichmann H. Jost WH, et al. Among authors: eggert k. Nervenarzt. 2022 Oct;93(10):1035-1045. doi: 10.1007/s00115-021-01237-3. Epub 2022 Jan 19. Nervenarzt. 2022. PMID: 35044481 Review. German.
Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.
Oertel WH, Müller HH, Unger MM, Schade-Brittinger C, Balthasar K, Articus K, Brinkman M, Venuto CS, Tracik F, Eberling J, Eggert KM, Kamp C, Kieburtz K, Boyd JT. Oertel WH, et al. Among authors: eggert km. NEJM Evid. 2023 Sep;2(9):EVIDoa2200311. doi: 10.1056/EVIDoa2200311. Epub 2023 Aug 22. NEJM Evid. 2023. PMID: 38320207 Clinical Trial.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Pain in Parkinson's Disease: Current Concepts and a New Diagnostic Algorithm.
Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, Beer S, Kesselring J, Stamelou M, Oertel WH, Möller JC, Lefaucheur JP. Mylius V, et al. Among authors: eggert km. Mov Disord Clin Pract. 2015 Aug 9;2(4):357-364. doi: 10.1002/mdc3.12217. eCollection 2015 Dec. Mov Disord Clin Pract. 2015. PMID: 30363602 Free PMC article. Review.
VRS2 regulates hormone-mediated inflorescence patterning in barley.
Youssef HM, Eggert K, Koppolu R, Alqudah AM, Poursarebani N, Fazeli A, Sakuma S, Tagiri A, Rutten T, Govind G, Lundqvist U, Graner A, Komatsuda T, Sreenivasulu N, Schnurbusch T. Youssef HM, et al. Among authors: eggert k. Nat Genet. 2017 Jan;49(1):157-161. doi: 10.1038/ng.3717. Epub 2016 Nov 14. Nat Genet. 2017. PMID: 27841879
Development and Validation of a Prognostic Model to Predict Overall Survival in Multiple System Atrophy.
Eschlboeck S, Goebel G, Eckhardt C, Fanciulli A, Raccagni C, Boesch S, Djamshidian A, Heim B, Mahlknecht P, Mair K, Nachbauer W, Scherfler C, Stockner H, Poewe W, Seppi K, Kiechl S, Wenning G, Krismer F; and the EMSA‐SG NHS Investigators; Barone P, Pellecchia MT, Quinn NP, Fowler CJ, Schrag A, Giladi N, Gurevich T, Ostergaard K, Widner H, Oertel W, Albanese A, Tolosa E, Deuschl G, Klockgether T, Dodel R, Sampaio C, Melamed E, Gasser T, Colosimo C, Rascol O, Meissner W, Tison F, Geser F, Duerr S, Boesch S, Köllensperger M, Koukouni V, Mathias CJ, Dupont E, Nilsson CF, Eggert KM, Del Sorbo F, Cardozo A, Hellriegel H, Coelho M, Djaldetti R, Kamm C, Meco G. Eschlboeck S, et al. Among authors: eggert km. Mov Disord Clin Pract. 2023 Jul 17;10(9):1368-1376. doi: 10.1002/mdc3.13822. eCollection 2023 Sep. Mov Disord Clin Pract. 2023. PMID: 37772304 Free PMC article.
124 results